KalVista Pharmaceuticals, Inc.
KALV · NASDAQ
9/30/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $243 | $124 | $99 | $167 |
| Short-Term Investments | $66 | $67 | $89 | $86 |
| Receivables | $7 | $6 | $15 | $9 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $8 | $8 | $39 | $5 |
| Total Curr. Assets | $325 | $206 | $242 | $267 |
| Property Plant & Equip (Net) | $12 | $7 | $2 | $7 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $2 | $2 | $7 | $1 |
| Total NC Assets | $15 | $10 | $9 | $9 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $340 | $216 | $251 | $276 |
| Liabilities | – | – | – | – |
| Payables | $8 | $6 | $5 | $6 |
| Short-Term Debt | $1 | $2 | $2 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $12 | $11 | $11 | $0 |
| Other Curr. Liab. | $24 | $19 | $27 | $18 |
| Total Curr. Liab. | $45 | $38 | $45 | $26 |
| LT Debt | $148 | $4 | $4 | $4 |
| Deferred Rev, NC | $0 | $0 | $106 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $130 | $132 | $0 | $101 |
| Total NC Liab. | $278 | $136 | $110 | $105 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $11 | $6 | $6 | $6 |
| Total Liabilities | $323 | $175 | $155 | $131 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$739 | -$713 | -$653 | -$601 |
| AOCI | -$7 | -$6 | -$5 | -$2 |
| Other Equity | $763 | $760 | $754 | $748 |
| Total Equity | $17 | $41 | $95 | $145 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $340 | $216 | $251 | $276 |
| Net Debt | -$94 | -$118 | -$92 | -$162 |